Tscan Therapeutics Inc (TCRX)
TScan Therapeutics, Inc. is a clinical-stage biotechnology company listed on NASDAQ under the ticker TCRX. The company focuses on developing T cell receptor-engineered T cell, or TCR-T, therapies for patients with cancer. Its lead candidate, TSC-101, is being evaluated in a Phase I clinical trial for patients with acute myeloid leukemia, myelodysplastic syndrome, and acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation. TSC-101 is also intended to help eliminate residual disease and support donor chimerism. TScan is also advancing TSC-102-A01 and TSC-102-A03, as well as a series of programs including TSC-200 through TSC-204 for solid tumor indications. In addition, the company has a research collaboration and license agreement with Amgen focused on identifying antigens recognized by T cells in Crohn’s disease. TScan Therapeutics was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TCRX
|
$1.32
|
40.9% Upside
|
Undervalued
|
$6
|
538.3% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 19, 2026
|
-0.5x
|
0.6x
|
6.7x
|
60.423 M
|
25.91 M
|
60.6%
|
84.8%
|
-4.7
|
—
|
100.5%
|
